BUDGET IMPACT ANALYSIS OF DIFFERENT TREATMENT MODALITIES AND THEIR COST- EFFECTIVENESS IN SAUDI HEALTH CARE SETTING
Main Article Content
Keywords
Obesity, Bariatric Surgery, Tirzepatide, Semaglutide, Liraglutide, ICER analysis, Budget Impact analysis.
Abstract
Objectives: To estimate the cost effectiveness of pharmacological and non-pharmacological (mainly surgery) regimens for the management of obesity.
Methods: an observation study was planned to attain the objectives of this study. Data from various hospitals regarding the interventions were collected to perform cost analysis. ICER and budget impact analysis were performed using the standard guidelines mentioned by the international society of pharmacoeconomic outcomes and research (ISPOR). Statistical analysis was performed using ANOVA and Chi-square wherever applicable. P-value less than 0.05 was considered statistically significant.
Results: The cost of Bariatric Surgery was 1041.67 SAR per kg weight loss and for 52 weeks the cost of surgery was 25000 SAR for 52 weeks. Surgical interventions were proven to be the most effective modalities with higher success rate in response to ever diem spend (p=<0.001). However, in the case when budgetary constraints are there for that specific group of population Semaglutide serves as the effective pharmacotherapy methods in terms of value for money. ICER analysis was performed to identify the most expensive and least effective regimen. Analysis has revealed that the ICER for Tirzepatide vs. Semaglutide was 5,909 / kg, while for Liraglutide vs. Semaglutide the effect was not desirable and there was no decline in weight. In terms of 5 years’ budget impact Tirzepatide was the highest, followed by Liraglutide and Semaglutide emerged as the most affordable regimen. For surgical intervention the upfront impact of Bariatric Surgery was 26.25 million SAR.
Conclusion: Bariatric Surgery where the main aim is immediate reduction in weight for high-risk patients the 5-year burden on the national health budget will be 26.25 million SAR. The willingness to pay, which is very important in the context of the budget impact analysis, If it is assumed that Saudi population struggling with obesity is willing to pay 2000 SAR per kg lost, then in this case both Semaglutide and Surgery are considered "High Value and Tirzepatide which is superior in comparison to Liraglutide, may require potential price negotiation to reach parity with Semaglutide.
References
2. Alluhidan, M.; Alsukait, R. F.; Alghaith, T.; Saber, R.; Alamri, A.; Al-Muhsen, S.; Alhowaitan, F.; Alqarni, A.; Herbst, C. H.; Alazemi, N. Frontiers in Public Health 2022, 10, 875941.
3. Salem, V.; AlHusseini, N.; Abdul Razack, H. I.; Naoum, A.; Sims, O. T.; Alqahtani, S. A. Obesity Reviews 2022, 23, (7), e13448.
4. Divino, V.; Ramasamy, A.; Anupindi, V. R.; Eriksen, K. T.; Olsen, A. H.; DeKoven, M.; Meincke, H. H. Journal of Managed Care & Specialty Pharmacy 2021, 27, (2), 210-222.
5. Althumiri, N. A.; Basyouni, M. H.; AlMousa, N.; AlJuwaysim, M. F.; Almubark, R. A.; BinDhim, N. F.; Alkhamaali, Z.; Alqahtani, S. A. In Obesity in Saudi Arabia in 2020: prevalence, distribution, and its current association with various health conditions, Healthcare, 2021; MDPI: p 311.
6. Alqahtani, S. A.; Al-Omar, H. A.; Alshehri, A.; Abanumay, A.; Alabdulkarim, H.; Alrumaih, A.; Eldin, M. S.; Schnecke, V. Advances in Therapy 2023, 40, (3), 1114-1128.
7. Alwin Robert, A.; Abdulaziz Al Dawish, M.; Braham, R.; Ali Musallam, M.; Abdullah Al Hayek, A.; Hazza Al Kahtany, N. Current diabetes reviews 2017, 13, (1), 59-64.
8. Malkin, J. D.; Baid, D.; Alsukait, R. F.; Alghaith, T.; Alluhidan, M.; Alabdulkarim, H.; Altowaijri, A.; Almalki, Z. S.; Herbst, C. H.; Finkelstein, E. A. PLoS One 2022, 17, (3), e0264993.
9. Federation, W. Trends, Costs and Country Reports 2020.
10. Khan, M. B.; Iqbal, S., Vision 2030 and the national transformation program. In Research, innovation and entrepreneurship in Saudi Arabia, Routledge: 2020; pp 146-166.
11. Alasiri, A. A.; Mohammed, V. Health services insights 2022, 15, 11786329221121214.
12. Al-Qahtani, D. A.; Imtiaz, M. L.; Shareef, M. M. Saudi medical journal 2005, 26, (8), 1260-1268.
13. Al-Maatouq, M. A. Saudi Med J 2005, 26, (5), 824-829.
14. Alhowiti, A.; Mirghani, H.; Abdulrahman Qrmli, A.; Albalawi, A. A.; Abdulrahman Aljohani, R. Frontiers in Pharmacology 2025, 16, 1510554.
15. Alsulami, S.; Baig, M.; Ahmad, T.; Althagafi, N.; Hazzazi, E.; Alsayed, R.; Alghamdi, M.; Almohammadi, T. Frontiers in Public Health 2023, 11, 1124051.
16. Wilding, J. P.; Batterham, R. L.; Davies, M.; Van Gaal, L. F.; Kandler, K.; Konakli, K.; Lingvay, I.; McGowan, B. M.; Oral, T. K.; Rosenstock, J. Diabetes, Obesity and Metabolism 2022, 24, (8), 1553-1564.
17. Wilding, J. J Med 2021, 384, 989-1002.
18. Jastreboff, A. M.; Aronne, L. J.; Ahmad, N. N.; Wharton, S.; Connery, L.; Alves, B.; Kiyosue, A.; Zhang, S.; Liu, B.; Bunck, M. C. New England Journal of Medicine 2022, 387, (3), 205-216.
19. (SFDA)., S. F. a. D. A. The SFDA's Comprehensive Approach to Health and Nutrition: Exploring the Multifaceted Food Strategy to Tackle Obesity and Improve Public Health. https://www.sfda.gov.sa/en/node/93311#:~:text=The%20SFDA's%20Comprehensive%20Approach%20to,Obesity%20and%20Improve%20Public%20Health (10 Jan),
20. Steenackers, N.; Toumassian, J.; Deleus, E.; Mertens, A.; Lannoo, M.; Pazmino, S.; van Laar, A. D. E.; Van der Schueren, B.; Vangoitsenhoven, R. Frontiers in Endocrinology 2025, Volume 16 - 2025.
21. Al-Omar, H. A.; Alshehri, A.; Abanumay, A.; Alabdulkarim, H.; Alrumaih, A.; Eldin, M. S.; Alqahtani, S. A. Adv Ther 2023, 40, (4), 1430-1443.
22. Sullivan, S. D.; Mauskopf, J. A.; Augustovski, F.; Jaime Caro, J.; Lee, K. M.; Minchin, M.; Orlewska, E.; Penna, P.; Rodriguez Barrios, J.-M.; Shau, W.-Y. Value in Health 2014, 17, (1), 5-14.
23. Khalaf, R. M.; Alghamdi, H. A. Cureus 2024, 16, (8).
24. AlGamdi, K.; AlQahtani, F.; AlShangiti, A.; Qabbani, B.; AlDumri, A.; AlRamadan, Y.; AlSaab, S.; AlHajjaj, A.; AlAtawi, W.; AlOudah, A. Archives of Pharmacy Practice 2022, 13, (1-2022), 55-62.
25. Wilding, J. P.; Batterham, R. L.; Calanna, S.; Davies, M.; Van Gaal, L. F.; Lingvay, I.; McGowan, B. M.; Rosenstock, J.; Tran, M. T.; Wadden, T. A. New England Journal of Medicine 2021, 384, (11), 989-1002.
26. Alhussain, K.; Alshakhs, Z.; Albaqshi, L.; Alshaqaqiq, F.; Alrabiah, M.; Tripathi, R. Healthcare (Basel) 2026, 14, (3).
27. Papantoniou, P.; Maniadakis, N. Front Public Health 2025, 13, 1690211.
28. Tan, X.; Brady, B. L.; Xie, L.; Paprocki, Y. Diabetes Ther 2025, 16, (7), 1417-1433.
29. Alhussain, K.; Alshakhs, Z.; Albaqshi, L.; Alshaqaqiq, F.; Alrabiah, M.; Tripathi, R. Healthcare 2026, 14, (3), 345.
30. Aronne, L. J.; Horn, D. B.; le Roux, C. W.; Ho, W.; Falcon, B. L.; Gomez Valderas, E.; Das, S.; Lee, C. J.; Glass, L. C.; Senyucel, C. N Engl J Med 2025, 393, (1), 26-36.
31. Gortmaker, S. L.; Wang, Y. C.; Long, M. W.; Giles, C. M.; Ward, Z. J.; Barrett, J. L.; Kenney, E. L.; Sonneville, K. R.; Afzal, A. S.; Resch, S. C.; Cradock, A. L. Health Aff (Millwood) 2015, 34, (11), 1932-9.
32. Summit., E. O. Obes Facts 2016, 9 Suppl 1, (Suppl 1), 1-376.
33. Murshid, M. Y.; Murshid, E. M.; Bukhari, N.; Alfayez, M.; Salah, T.; Bahadur, Y. Annals of Medicine and Surgery 2026, 88, (3), 2335-2347.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Almeman A Ahmed
Pharmacology and Therapeutic Department, College of Medicine, Al-Qassim University, Qassim, Saudi Arabia
Humera Tahir
Ruth Pfau College of Nutrition, Lahore University of Biological and Applied Sciences (UBAS), Lahore Pakistan.
Alayoubi FZ
College of Medicine, King Saud University, Riyadh, Saudi Arabia
Almutairi AT
Department of Pharmacy, King Khalid General Hospital Riyadh, Saudi Arabia
Aldaweesh SI
Department of Pharmacy, Security Forces Hospital, Riyadh, Saudi Arabia
Alhuwatan SS
Department of Pharmacy, Lean Business Services, Riyadh, Saudi Arabia
Alrashed SA
Department of Pharmacy, Middle East Pharmaceutical Company Avalon Pharma, Riyadh, Saudi Arabia
Alharbi MA
Department of Pharmacy, Cooper Consumer Health, Riyadh, Saudi Arabia.
Alghamdi RA
College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia
